We rank companies based on fund manager, research analyst and news sentiment
AMRN

Amarin Corp Plc
AMRN

$0.96
6.86%
 

About: Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Employees: 275

0
Funds holding %
of 6,474 funds
Analysts bullish %
0
News positive %
of 6 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

82% more call options, than puts

Call options by funds: $340K | Put options by funds: $186K

0.91% more ownership

Funds ownership: 23.27% [Q3] → 24.18% (+0.91%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

0% less capital invested

Capital invested by funds: $82.9M [Q3] → $82.6M (-$237K) [Q4]

3% less funds holding

Funds holding: 181 [Q3] → 175 (-6) [Q4]

16% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 45

25% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 24

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$1
4%
upside
Avg. target
$1
4%
upside
High target
$1
4%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Jefferies
Michael Yee
4%upside
$1
Hold
Downgraded
25 Oct 2023

Financial journalist opinion

Based on 6 articles about AMRN published over the past 30 days